| 0 (0%) | 01-19 18:54 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 67.08 | 1-year : | 70.93 |
| Resists | First : | 57.43 | Second : | 60.72 |
| Pivot price | 55.07  |
|||
| Supports | First : | 52.09 | Second : | 43.34 |
| MAs | MA(5) : | 55.21 |
MA(20) : | 55.39 |
| MA(100) : | 58.8 |
MA(250) : | 50.46  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 32 |
D(3) : | 40.3 |
| RSI | RSI(14): 44.1 |
|||
| 52-week | High : | 78.48 | Low : | 30.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRSP ] has closed above bottom band by 26.8%. Bollinger Bands are 41.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 54.81 - 55.11 | 55.11 - 55.36 |
| Low: | 52.38 - 52.75 | 52.75 - 53.06 |
| Close: | 52.95 - 53.52 | 53.52 - 53.99 |
Sat, 17 Jan 2026
Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Gene Editing Progress? - simplywall.st
Fri, 16 Jan 2026
Nwam LLC Purchases 83,454 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Fri, 16 Jan 2026
Crispr Therapeutics AG (CRSP) Gets a Buy from Bank of America Securities - The Globe and Mail
Thu, 15 Jan 2026
How CRISPR Therapeutics’ Expanding Gene-Editing Pipeline and CTX310 Trial Progress Will Impact CRSP Investors - simplywall.st
Thu, 15 Jan 2026
CRISPR Therapeutics (CRSP) is considered a good investment by brokers: Is that true? - MSN
Thu, 15 Jan 2026
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 9.484e+007 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 23,190 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.5948e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 854.7 % |
| Return on Equity (ttm) | -13.3 % |
| Qtrly Rev. Growth | 3.834e+007 % |
| Gross Profit (p.s.) | 27.57 |
| Sales Per Share | -14.65 |
| EBITDA (p.s.) | -2.48942e+008 |
| Qtrly Earnings Growth | -5.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -302 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -3.66 |
| Price to Cash Flow | 4.53 |
| Dividend | 0 |
| Forward Dividend | 2.186e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|